13F Holdings
中文EN

TLPH TALPHERA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1427925 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-96.3%
TTM net income YoY-33.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,474,700.0%
Net margin-1,507,600.0%
FCF margin—
EBITDA margin—

Returns

ROE-143.4%
ROA-69.6%
ROIC (approx.)-172.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets46.3%
Debt / equity0.00x
Current ratio4.29x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-13.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$28,000$0$651,000$0$2.82M
Cost of revenue———$2.59M$3.75M
Gross profit———-$2.59M-$935,000
R&D expense$6.03M$6.72M$5.55M$3.34M$4.09M
SG&A expense$7.48M$8.53M$11.99M$17.01M$30.93M
Operating income-$13.48M-$15.25M-$16.89M-$25.30M-$35.97M
Interest expense—$0$134,000$1.12M$2.29M
Pretax income——-$10.29M$59.14M-$35.09M
Income tax$0$0$0$13,000$5,000
Net income-$14.29M-$13.00M-$18.40M$47.76M-$35.10M
EBITDA—-$15.25M-$16.58M-$23.65M-$33.99M
EPS (basic)-0.34-0.50-1.295.73-5.86
EPS (diluted)——-1.295.72-5.86
Weighted avg. shares (diluted)——14.26M7.41M5.99M
Balance sheet
Cash & equivalents$5.89M$8.86M$5.72M$15.28M$7.66M
Short-term investments$14.49M$0$3.66M$495,000$38.97M
Receivables———$309,000$160,000
Inventory———$1.18M$1.11M
Current assets$20.90M$9.42M$11.58M$24.57M$50.49M
PP&E, net———$10.26M$15.93M
Intangibles$8.82M$8.82M$8.82M$8.82M$0
Total assets$29.72M$18.24M$20.39M$47.49M$77.89M
Current liabilities$3.81M$2.65M$4.51M$13.77M$18.51M
Short-term debt——$0$5.36M$8.80M
Long-term debt———$0$5.01M
Total debt———$5.36M$13.80M
Total liabilities$12.68M$10.23M$6.29M$25.67M$113.79M
Shareholders' equity$17.04M$8.00M$14.11M$21.81M-$35.89M
Net debt———-$9.91M$6.14M
Shares outstanding49.33M17.03M16.95M8.24M6.84M
Cash flow statement
Operating cash flow-$11.36M-$12.68M-$17.49M-$28.33M-$30.00M
Capital expenditure—$0$100,000$364,000$1.83M
Free cash flow—-$12.68M-$17.59M-$28.70M-$31.83M
Investing cash flow-$14.35M$3.78M-$528,000$36.45M-$26.12M
Financing cash flow$22.74M$12.04M$3.47M-$507,000$41.51M
Depreciation & amortization—$0$311,000$1.65M$1.97M
Stock-based compensation$699,000$989,000$1.73M$2.89M$4.61M

Free plan shows the latest 5 periods; Pro shows all 20 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.